Skip to content
🎯⭐ INTERACTIVE LESSON

Research Methods & Study Design

Learn step-by-step with interactive practice!

Research Methods & Study Design - Complete Interactive Lesson

Part 1: Variables, Sampling & Study Types

Research Methods & Study Design

Part 1 of 4 — Variables, Sampling & Study Types

Types of Variables

Variable TypeDefinitionExample
Independent Variable (IV)What the researcher manipulatesDrug dose, light exposure, temperature
Dependent Variable (DV)What the researcher measures as an outcomePatient recovery time, test score, enzyme activity
Confound VariableUncontrolled variable related to BOTH the IV and the DVAge, baseline health status, socioeconomic status

Sampling Methods

MethodDescriptionBias Risk
Random SamplingEvery member of the population has an equal chance of selectionLow bias; representative
Convenience SamplingEasiest to access (first n patients)High bias; may not represent population
Stratified SamplingDivide population into groups, randomly sample each in proportionLower bias than convenience
Matching (matched pairs)A design control, not a true sampling method: pair participants on key variables, then compare or assign within pairsControls specific confounds; less effective than randomization

Study Types (by Causation Inference)

TypeDesignCausation Evidence
Experimental (RCT)Researcher manipulates IV, randomly assignsStrongest
Quasi-ExperimentalResearcher manipulates IV, no randomizationModerate
CorrelationalResearcher measures variables, finds associationWeak
ObservationalPassive observation; no manipulationWeak to moderate (cohort > case-control > cross-sectional)

Key: Only random assignment (RCT) can establish causation by balancing confounds.

Variables & Sampling 🎯

Key Takeaways — Part 1

  • IV = Independent Variable (what's manipulated); DV = Outcome (what's measured)
  • Confound = Uncontrolled variable related to both the IV and the DV
  • Random Assignment ⟹ RCT ⟹ Strongest causation inference (internal validity)
  • Random Sampling ⟹ Representative sample ⟹ Generalizability (external validity); convenience sampling weakens it
  • Sampling decides WHO is studied; assignment decides WHICH GROUP they join — only assignment supports causation
  • Matching (matched pairs) is a design control: it controls specific confounds but not unknown ones (inferior to randomization)

Worked Examples — Variables, Sampling & Study Types

<details> <summary><b>Example 1: Separate IV and DV cleanly</b></summary>

Question: Participants receive either 0 mg, 50 mg, or 100 mg caffeine, then complete a reaction-time test.

  1. Manipulated factor is caffeine dose.
  2. Measured outcome is reaction time.

IV: caffeine dose. DV: reaction time.

</details> <details> <summary><b>Example 2: Spot sampling bias</b></summary>

Question: A stress survey recruits only pre-med students from one campus.

  1. Recruitment is convenience-based and narrow.
  2. Sample likely differs from general population.

Main issue: selection/sampling bias, reducing external validity.

</details> <details> <summary><b>Example 3: Distinguish observational from experimental</b></summary>

Question: Researchers record average sleep and exam scores without assigning sleep schedules.

  1. No manipulation of sleep duration.
  2. No random assignment.

Design type: observational/correlational, not experimental.

</details>

Part 2: Validity & Threats to Validity

Research Methods & Study Design

Part 2 of 4 — Validity & Threats to Validity

Types of Validity

Validity TypeDefinitionExample
Internal ValidityCausal inference: Did IV cause the DV?Did drug (not age/diet) cause recovery?
External ValidityGeneralizability: Do results apply beyond the study?Do lab findings translate to real patients?
Construct ValidityDoes the measurement actually measure what it claims?Does IQ test truly measure "intelligence"?
Statistical Conclusion ValidityAre conclusions about relationships statistically sound?Is the sample large enough to detect effect?

Threats to Internal Validity

ThreatWhat it isExample
ConfoundingUncontrolled third variable, linked to both IV and DV, causes apparent effectTreated patients recover faster, but they were also younger (age drives recovery)
Selection BiasSystematic differences in groups before studyHealthier patients self-select into treatment group
AttritionDifferential dropout in groupsSicker subjects quit drug trial early
HistoryOutside event during the study affects the outcomeA public-health campaign launches mid-study and changes participants' behavior
MaturationSubjects change naturally over timePatients improve due to aging, not treatment

Threats to External Validity

ThreatImpact
Limited SampleResults may not generalize to other populations
Lab ConditionsArtificial environment ≠ real-world effects
Volunteer BiasVolunteers differ from general population
Interaction with IVEffect depends on specific conditions (works in winter, not summer)

Solution: Random assignment (internal validity) + Representative (random) sample (external validity)

Validity & Threats 🎯

Key Takeaways — Part 2

  • Internal Validity: Random assignment controls confounds, so a change in the DV can be attributed to the IV
  • External Validity: Representative sampling + diverse conditions enable generalization
  • Construct Validity: Measurement must truly measure the construct intended
  • Key Threats: Confounding, selection bias, attrition (internal); volunteer bias, lab conditions (external)
  • Ideal Study: Random assignment (strong internal) + Representative (random) sample (strong external)

Worked Examples — Validity & Threats

<details> <summary><b>Example 1: Internal vs external validity</b></summary>

Question: A tightly controlled inpatient trial shows strong results, but participants are all healthy young adults.

  1. Strong protocol control supports internal validity.
  2. Narrow participant profile limits generalization.

Result: high internal validity, weaker external validity.

</details> <details> <summary><b>Example 2: Identify attrition bias</b></summary>

Question: In a weight-loss trial, dropout is 35% in treatment vs 8% in control.

  1. Unequal dropout changes who remains in each group.
  2. Final comparison can be biased.

Threat: attrition bias.

</details> <details> <summary><b>Example 3: Construct validity check</b></summary>

Question: "Empathy" is measured only by number of social media comments posted.

  1. Metric may not map to the intended construct.
  2. Behavior proxy is weak and noisy.

Main concern: construct validity.

</details>

Part 3: Blinding & Experimental Controls

Research Methods & Study Design

Part 3 of 4 — Blinding & Experimental Controls

Blinding in Studies

TypeWho is Blinded?Effect
No BlindingParticipants & researchers know treatmentExpectations differ between groups + researcher bias
Single-BlindParticipants don't know (researcher knows)Equalizes placebo effect across groups; researcher may bias
Double-BlindBoth participants & researchers don't knowGold standard; minimizes bias

Mechanism of Placebo Effect: Brain expectation → neurotransmitter release → real physiological changes. Blinding does not abolish the placebo effect; it makes it equal in both arms so a placebo control can subtract it.

<!-- yield:low -->
  • Typical placebo response rates are often quoted at roughly 30-40% of patients, though the figure varies widely by condition and outcome.
<!-- /yield -->

Placebo & Control Groups

GroupPurpose
Placebo ControlIsolates IV effect from placebo effect
Active ControlCompares new drug to gold-standard treatment (ethical)
No-Treatment ControlMeasures natural recovery/maturation
Waitlist ControlEthical alternative for beneficial treatments

Example: Depression RCT

  • Placebo group: 30% improve (placebo effect + natural recovery)
  • Antidepressant group: 60% improve
  • True drug effect = 60% − 30% = 30%

Types of Experimental Designs

DesignStructureUse Case
Within-SubjectsSame subjects in all conditionsMeasures change pre-post (power maximized)
Between-SubjectsDifferent subjects per conditionNo carryover effects; larger N needed
FactorialMultiple IVs tested simultaneouslyEfficiency; can detect interactions
LongitudinalFollow subjects over timeTracks development, long-term effects

Carryover Effect: Practice in Condition A affects performance in Condition B. Counterbalance (or randomize) the order, or use a between-subjects design.

Blinding & Controls 🎯

Key Takeaways — Part 3

  • Double-Blind > Single-Blind > No Blinding (equalizes expectancy effects across groups + minimizes researcher bias)
  • Placebo Control isolates IV effect by subtracting baseline placebo response
  • Within-Subjects design increases power (subjects are own controls); risk of carryover effects
  • Between-Subjects design avoids carryover; requires larger N
  • MCAT Tip: Always check: Is the study blinded? Is there a placebo control? Could carryover effects bias results?

Worked Examples — Blinding & Experimental Controls

<details> <summary><b>Example 1: Why double-blind helps</b></summary>

Question: In a pain trial, nurses who know treatment assignment rate pain outcomes more favorably for the drug group.

  1. Knowledge of assignment can influence ratings.
  2. Blinding raters removes expectancy effects.

Fix: use a double-blind design.

</details> <details> <summary><b>Example 2: Compute true treatment effect from placebo baseline</b></summary>

Question: Placebo improves 25%; drug improves 55%.

  1. Total observed drug-group response includes placebo component.
  2. Subtract placebo baseline.

Estimated drug-specific effect: 30 percentage points.

</details> <details> <summary><b>Example 3: Carryover in within-subjects design</b></summary>

Question: Subjects take memory test after caffeine in week 1 and after placebo in week 2. Scores improve in week 2.

  1. Practice effects can increase later scores independent of treatment.
  2. Order effects threaten interpretation.
  3. Counterbalancing or between-subjects design can reduce this issue.

Threat identified: carryover/order effect.

</details>

Part 4: Sample Size, Ethics & Meta-Analysis

Research Methods & Study Design

Part 4 of 4 — Sample Size, Ethics & Meta-Analysis

Sample Size & Power

Larger sample → More power to detect true effects (↓β, Type II error)

FactorEffect on Power
Larger sample size↑ Power
Larger effect size↑ Power
Lower variability↑ Power
Higher α (0.05 vs 0.01)↑ Power

Rule of thumb: Aim for 80%+ power (β ≤ 20%).

Research Ethics (MCAT focus: Belmont Principles, Informed Consent, IRB)

Principle / SafeguardRequirement
Respect for Persons (Autonomy)Informed consent: subjects understand risks/benefits; participation is voluntary
BeneficenceMaximize benefits; minimize harms (nonmaleficence: do no harm)
JusticeFair distribution of risks/benefits; equitable access
IRB (Institutional Review Board)Ethical review before study starts

Special Populations: Extra protections for children, prisoners, and the cognitively impaired (consent may be limited or open to coercion; children give assent alongside parental permission)

Vulnerable Populations: Cannot be excluded from research solely for "protection"; must justify any exclusion

Meta-Analysis

Combines data from multiple studies to increase statistical power.

Advantage: Large sample → more generalizable conclusions
Risk: Publication bias (positive findings more likely to be published)
IssueImpact
HeterogeneityStudies differ in methods; may not combine
Publication BiasNull findings ↓ published; overestimates effect
Quality VariationPoor-quality studies can bias pooled analysis

Forest Plot Interpretation: Vertical line at 1.0 (OR) means no effect; if the pooled confidence interval crosses it, the effect is not significant overall.

Sample Size, Ethics & Meta-Analysis 🎯

Key Takeaways — Part 4

  • Sample Size: Larger N → More power (can detect small true effects)
  • Power Goal: 80%+ (Type II error rate β ≤ 20%)
  • Belmont Principles: Respect for persons (informed consent), beneficence, justice
  • Informed Consent: Disclosure of risks/benefits; voluntary; ability to withdraw
  • Vulnerable Populations: Include with extra protections, don't exclude
  • Meta-Analysis: Combines studies for power, but publication bias can overestimate effects
  • Forest Plots: If CI crosses 1.0 (OR), effect is not statistically significant
  • MCAT Tip: Ethics questions focus on consent, IRB review, protection of vulnerable groups

Worked Examples — Power, Ethics & Meta-Analysis

<details> <summary><b>Example 1: Increase power in a weak study</b></summary>

Question: Trial with n=40 per arm yields p=0.09 for a moderate effect.

  1. Small sample can underpower the test.
  2. Increasing n reduces standard error.
  3. Better power improves chance of detecting a true effect.

Most direct improvement: larger sample size.

</details> <details> <summary><b>Example 2: Informed consent essentials</b></summary>

Question: A participant signs a form but was never told key side effects.

  1. Signature alone is insufficient.
  2. Valid consent requires meaningful disclosure and understanding.

Ethics issue: informed consent was inadequate.

</details> <details> <summary><b>Example 3: Read a forest plot threshold</b></summary>

Question: Pooled odds ratio is 0.85 with 95% CI 0.62 to 1.10.

  1. For OR, null value is 1.0.
  2. CI crosses 1.0.
  3. Pooled effect is not statistically significant.

Interpretation: possible benefit, but inconclusive overall.

</details>